Plain-English translation of NCT04806464 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called VG161 for people with advanced liver cancer that hasn't responded to standard treatments or for whom no standard treatment exists. The trial will first test increasing doses of the medication in a small group of patients to find the safest and most effective dose. Then, a second phase will test the recommended dose in more patients to see how well it works.
Advanced liver cancer is a serious disease, and many patients either stop responding to standard treatments or cannot tolerate them. This trial exists to see whether this new treatment could offer hope to patients who have run out of other options.
You likely qualify if…
You likely don't qualify if…
In the first phase, you would receive injections of the medication directly into your tumor over 1 to 3 days, starting with smaller doses in the first group and increasing in later groups. Doctors will monitor you closely to see how you tolerate the treatment and watch for side effects. If a safe and promising dose is found, a second phase will test that dose in more patients to better understand how well it works.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China